National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Rapid Review

Commenced Completed Outcome
06/02/2017 24/04/2017 Full Pharmacoeconomic Evaluation Not Recommended.